Core Viewpoint - The ongoing dispute over exclusive agency rights between two companies, Ruoyuchen and Shuiyang, regarding the Spanish beauty brand Mesoestetic in China has raised questions about the legitimacy of their claims to exclusivity and has implications for the market dynamics of the oral beauty supplement sector [1][3][9]. Group 1: Company Developments - Ruoyuchen has announced it will become the exclusive general agent for Mesoestetic's oral beauty health product line in China, with irrevocable trademark rights and related authorizations, effective from January 1, 2026, to December 31, 2028 [1]. - Shuiyang, which has been the exclusive distributor for Mesoestetic since 2021, claims it remains the brand's exclusive distributor in China and is currently in discussions with the brand regarding the ongoing contract [1][5]. - The dispute has led to confusion in the market, with both companies asserting their exclusive rights, prompting inquiries from media sources [1][3]. Group 2: Market Impact - There has been a significant price reduction for Mesoestetic products, with reports of discounts up to 50% compared to previous prices, which some consumers attribute to the agency rights dispute [3][6]. - Ruoyuchen clarified that the current price drop is not a brand initiative but rather actions taken by the previous distributor, Shuiyang, and emphasized their commitment to maintaining market order and brand integrity [3][6]. - The oral beauty market in China is projected to grow significantly, with estimates suggesting it will exceed 25.57 billion yuan by 2025, reflecting a stable annual growth rate of over 3.8% [9].

Core Insights - The Chinese medical aesthetics industry in 2025 will be defined by "compliance foundation" and "value reassessment" [2] - The shift from a "flow-driven" model to a "technology-driven" model is evident, with an emphasis on the importance of regulatory compliance and technological advancements [2][3] Regulatory Normalization - Regulatory normalization is becoming the core theme of the medical aesthetics industry, with policies reshaping development logic [3] - The release of the "Guidelines for the Pricing of Cosmetic Surgery Medical Services" by the National Medical Insurance Administration standardizes 101 pricing items, addressing issues like "same item different price" [3] - Over 18,000 illegal institutions were shut down, and 327 physicians had their licenses revoked, indicating a shift from sporadic regulation to ongoing purification [3][4] Cross-Industry Capital Involvement - The entry of cross-industry capital is reshaping the compliance landscape and highlighting the long-term value of upstream technology [5] - A strategic investment of 3.403 billion yuan by Zhong Shanshan's Yangshengtang in Jinbo Biological marks a significant milestone in the industry, with Zhong becoming the second-largest shareholder [5][6] - This investment reflects a merging of "technology" and "channel," aiming to leverage Jinbo's unique technology in collagen production with Yangshengtang's extensive distribution network [6][7] Intensifying Competition - The medical aesthetics industry is experiencing intensified competition over core product control, leading to conflicts between brands and distributors [9] - A significant arbitration case between Aimeike and Jiangsu Wuzhong over exclusive agency rights for a key product highlights the ongoing struggle for market control [9][10] - The outcome of such disputes will significantly impact market dynamics and the distribution of profits within the industry [11] Future Landscape - The industry is expected to undergo consolidation and innovation in business models, with leading chains capturing 30%-40% of the market share [13] - The integration of "medical aesthetics + health management" is anticipated to become mainstream, with a focus on preventive care among younger consumers [13] - Investors are advised to focus on upstream core technologies and compliant institutions with strong medical management capabilities, as the industry transitions to a more sustainable and professional era [13]

证券日报网讯12月25日，爱美客（300896）在互动平台回答投资者提问时表示，公司经营数据相关信 息，请以公司定期报告为准。 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 作为曾与华熙生物、爱美客齐名的国内"医美三剑客"之一，昊海生科凭借A+H双融资平台的资本优势及 在医美、眼科等高景气赛道的布局，一度成为市场瞩目的明星企业。 然而眼下，与其昔日光环相伴的，是核心业务增长引擎集体失速，为寻求突围而进行的并购交易疑窦丛 生，公司治理层面问题频发等。 业绩全面失速仍慷慨分红 控股股东成最大受益者 从业绩表现看，公司营收与净利润已连续多个季度同比下滑。2025年前三季度，公司实现营业收入 18.99亿元，同比下降8.47%；实现归母净利润3.05亿元，同比下降10.63%；实现扣非归母净利润2.55亿 元，同比下降20.75%。 结合业务看，营收占比最大的医美板块增长疲态已有所显现。核心产品玻尿酸销售收入上半年仅为3.47 亿元，同比大幅下滑16.8%。尽管公司推出了第四代有机交联玻尿酸等新产品，但在行业整体消费需求 不足、价格竞争日趋白热化以及监管环境变化的背景下，明星产品线增长乏力，短期内难以看到强劲的 复苏拐点。 眼科业务作为公司战略重心则遭遇政策与市场的双重夹击。一方面，2023年11月，业务核心产品人 ...

南财智讯12月25日电，爱美客公告，公司拟对部分募集资金投资项目进行延期。涉及项目包括"基因重 组蛋白研发生产基地建设项目"，计划投资金额16,000.00万元，资金来源为首次公开发行股票募集资 金，用途为建设基因重组蛋白药物研发生产基地，因项目选址、生产工艺及投产时间等关键事项尚在论 证中，尚未开工，故将预定可使用状态日期由2025年12月31日延期至2027年12月31日；另一项目为"注 射用A型肉毒毒素研发项目"，计划投资金额12,000.00万元，资金来源相同，用途为研发注射用A型肉毒 毒素，因该产品注册上市申请尚在评审审批阶段，预计需较长时间，故将预定可使用状态日期由2025年 12月31日延期至2026年12月31日。本次延期未改变项目实施主体、投资总额及募集资金用途，不构成募 投资金用途变更，不影响公司主营业务发展和整体募资安排，不会对公司财务状况和正常经营产生不利 影响，符合公司长期发展规划。 ...

证券代码：300896 证券简称：爱美客 公告编号：2025-055 号 结合目前募集资金投资项目的实际情况，在项目实施主体、募集资金投资用 途及投资规模都不发生变更的情况下，董事会同意将募集资金投资项目"基因重 组蛋白研发生产基地建设项目"预计可使用状态的日期由 2025 年 12 月 31 日延 长至 2027 年 12 月 31 日；董事会同意将募集资金投资项目"注射用 A 型肉毒毒 素研发项目"预计可使用状态的日期由 2025 年 12 月 31 日延长至 2026 年 12 月 31 日。 1 第四届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 爱美客技术发展股份有限公司（以下简称"公司"）第四届董事会第二次会 议于 2025 年 12 月 25 日在公司会议室以现场与通讯相结合方式召开。本次会议 应到董事 9 人，实到董事 9 人。董事长简军、董事石毅峰、简青、林新扬、陈重 和独立董事于玉群以通讯方式出席并进行表决。会议通知已于 2025 年 12 月 19 日通过邮件和电话的方式送达各位董事。 ...

证券代码：300896 证券简称：爱美客 公告编号：2025- 056 号 爱美客技术发展股份有限公司 关于部分募集资金投资项目延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 爱美客技术发展股份有限公司（以下简称"公司""爱美客"）于 2025 年 12 月 25 日召开第四届董事会第二次会议，审议通过了《关于部分募集资金投资 项目延期的议案》，公司拟在实施主体、募集资金用途等均维持不变的情况下， 对部分募集资金投资项目进行延期。现将相关事项公告如下： 根据《爱美客技术发展股份有限公司首次公开发行股票并在创业板上市招股 说明书》，公司本次公开发行股票募集资金扣除发行费用后，将投资以下项目： 单位：万元 | 募集资金投资项目 | 项目总投资 | 拟投入募集资 | 实际投入募集资金 | | --- | --- | --- | --- | | 序号 | | | | 一、募集资金基本情况 中国证券监督管理委员会于 2020 年 8 月 26 日出具证监许可[2020]1937 号 文，同意公司首次公开发行股票的注册申请。公司首次公开发行的人民币普通股 （A ...

中信证券股份有限公司 关于爱美客技术发展股份有限公司 部分募集资金投资项目延期的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）作为爱美客技 术发展股份有限公司（以下简称"爱美客"或"公司"）首次公开发行股票并在深圳 证券交易所创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 市公司募集资金监管规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等有关法律法规的要求，对公司部分募集资金投资项 目延期的事项进行了核查，具体情况如下： 中国证券监督管理委员会于2020年8月26日出具证监许可[2020]1937号文， 同意爱美客技术发展股份有限公司（以下简称"公司"）首次公开发行股票的注册 申请。公司首次公开发行的人民币普通股（A 股）股票已于 2020 年 9 月 28 日在 深圳证券交易所上市交易。 公司首次向社会公开发行的股票 3,020.00 万股，每股面值 1.00 元，发行价 格 118.27 元/股，募集资金总额为人民币 3,571,754,000.00 元，扣除与本次发行有 关的费用人民币（不含税）136,620,230.77 元，实 ...

Group 1 - The medical beauty sector increased by 0.38% compared to the previous trading day, with Aimeike leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] - The net outflow of main funds in the medical beauty sector was 13.718 million yuan, while retail investors saw a net inflow of 11.2799 million yuan [1] Group 2 - The net inflow of funds from speculative investors in the medical beauty sector was 2.4381 million yuan [1] - Detailed fund flow data for individual stocks in the medical beauty sector is available in the accompanying table [1]

Core Insights - The male aesthetic medicine market is rapidly growing, with male spending increasing by 27% year-on-year in 2023, indicating a shift in consumer demographics and preferences within the industry [6][21] - Despite the growth in male consumers, the overall aesthetic medicine industry faces challenges such as market saturation, intense competition, and declining profits among leading companies [2][4][13] Group 1: Market Trends - The number of aesthetic medicine-related enterprises in China exceeds 182,000, leading to fierce competition and price wars among providers [2] - Male consumers are increasingly seeking aesthetic procedures, with 43% of surveyed men planning to increase their spending in 2024, compared to 29% of women [7][21] - The average spending per male customer is 2.75 times that of female customers, highlighting a significant revenue potential in the male segment [14] Group 2: Industry Challenges - Leading companies like Ai Meike have reported consecutive declines in profits, reflecting broader industry struggles with overcapacity and market competition [4][13] - The industry is experiencing a trust crisis due to incidents of malpractice and regulatory tightening, which has led to increased scrutiny and the need for clearer consumer protection measures [3][19] Group 3: Consumer Behavior - Male consumers tend to focus on specific, functional aesthetic treatments, such as skin management and hair restoration, rather than ongoing maintenance, which poses a challenge for building long-term customer relationships [14][15] - The rise of social media has shifted perceptions of male aesthetics, with platforms like Douyin and Xiaohongshu driving interest and engagement in male aesthetic procedures [8][12] Group 4: Technological and Market Innovations - Internet giants like JD Health and Meituan are entering the male aesthetic market, leveraging their technological capabilities and consumer bases to enhance service accessibility and trust [17][20] - New service models, such as "lunch break beauty" procedures, cater to the male demographic's preference for efficiency and discretion [12][21] Group 5: Future Outlook - The male aesthetic market is seen as a potential growth area for the industry, but it is not a guaranteed solution to current challenges; establishing trust and ensuring quality service will be crucial for long-term success [21][22] - The market for customized male aesthetic treatments is projected to grow significantly, with estimates suggesting a market size of $8 billion for gene therapy by 2030 [14]